Dako Enters Collaboration With Eli Lilly and Company for Development of Companion Diagnostics
(firmenpresse) - GLOSTRUP, DENMARK -- (Marketwire) -- 01/07/13 -- Dako, an Agilent Technologies company, announced today it has entered into a master framework agreement with Eli Lilly and Company for the development of companion diagnostic tests to identify patients who may be more likely to benefit from an investigational oncology medicine currently under development by Lilly.
The agreement constitutes a framework for collaboration between Dako and Lilly with a focus on the Lilly oncology pipeline.
"Building lasting partnerships is a cornerstone to Dako," says Lars Holmkvist, CEO of Dako and senior vice president, Agilent. "I warmly welcome Lilly, and I am excited about what we may accomplish together for the benefit of patients worldwide. This agreement heralds our mutual commitment to fighting cancer."
Companion diagnostics are increasingly in demand with the recognition that personalized medicine may provide a way to improve patient care and manage health-care costs by targeting treatments to individuals more likely to benefit from specific therapies.
"Tailored therapies are a key component of Lilly's strategy of providing improved outcomes for individual patients," says Greg Zdechlik, chief operating officer, Diagnostics, Eli Lilly and Company. "We look forward to collaborating with Dako in an effort to develop oncology companion diagnostics for patients worldwide who are waiting."
Dako has a strong heritage of developing diagnostic tests in collaboration with pharmaceutical companies. The collaboration with Lilly is another example of Dako's position in the clinical diagnostics market as a strong partner for developing diagnostic tests for use in conjunction with medicines.
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at .
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at .
Maia Fredtoft Sochting
Dako
+45 25 46 10 83
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.01.2013 - 10:00 Uhr
Sprache: Deutsch
News-ID 1184714
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
GLOSTRUP, DENMARK
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako Enters Collaboration With Eli Lilly and Company for Development of Companion Diagnostics
"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
